Zimbabwe has declined a significant American health deal worth 367 million US dollars (£272m) over five years due to Washington's insistence on confidential information.
The decision became public after a government memo dated December was leaked, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesman later explained that the US was requesting health data for scientific study and profit while refused to guarantee the benefits from future medical innovations.
"We will now turn to the challenging and unfortunate task of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy noted the US had provided over $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has called for more talks to secure a agreement agreeable to both sides so the nation's critical HIV treatment initiative can be sustained.
Wider Implications
Zimbabwe's decision comes after a comparable situation in Kenya, where a high court suspended a similar health funding agreement after legal challenges were filed about the security of citizens' medical information.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
The agency had overseen aid for the American government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government deals to boost transparency and accountability.
According to reports, 16 African countries have so far agreed to these new agreements, representing more than $18.3bn in new funding.
Details of the Declined Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this cooperation might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving HIV treatment via American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent guarantee of benefiting from any medical innovations – such as new medicines or tests – that could result from that provided information," his statement read.
"Put simply, our country would provide the raw materials for scientific discovery with no certainty that the resulting innovations would be accessible to our people should a future pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were upending systems already set up through the international organization.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not monopolised solely by those with the capability to create them."
These objections over the US deal "are not meant as anti-American sentiment," he added.
"We encourage continued discussions with our US partners on how subsequent co-operation might be structured in a manner that respects the sovereignty and interests of each country."
Health Experts Reaction
Medical experts said it acknowledged the government's concerns, but urged that talks should continue considering a large portion of the country's HIV programmes relied on external financing.
"If technical issues arise, including those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it said.
This impasse emphasises the continuing challenges between accepting crucial international aid and safeguarding local interests in an increasingly interconnected world.